Mortality of neuroleptic malignant syndrome induced by typical and atypical antipsychotic drugs: A propensity-matched analysis from the Japanese Diagnosis Procedure Combination database

Journal of Clinical Psychiatry

Volumn 73, Issue 4, 2012, Pages 427-430

  Nakamura, Mitsuhiro ^a,b   Yasunaga, Hideo ^b   Miyata, Hiroaki ^b   Shimada, Takafumi ^b   Horiguchi, Hiromasa ^b   Matsuda, Shinya ^c  

^a Yamazumi Hospital   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

^c UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; NEUROLEPTIC AGENT;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; FEMALE; HUMAN; JAPANESE; MAJOR CLINICAL STUDY; MALE; MORTALITY; NEUROLEPTIC MALIGNANT SYNDROME; PATIENT IDENTIFICATION; PRIORITY JOURNAL; PROGNOSIS; PROPENSITY SCORE;

EID: 84860596511     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.10m06791     Document Type: Article

References (20)

1. Strawn JR, Keck PE Jr, Caroff SN. Neuroleptic malignant syndrome. Am J Psychiatry. 2007;164(6):870-876. doi:10.176/api.ajp.164.6.870 PubMed (Pubitemid 46972900)
2. Levenson JL. Neuroleptic malignant syndrome. Am J Psychiatry. 1985;142(10):1137-1145. PubMed (Pubitemid 16223648)
3. Trollor JN, Chen X, Sachdev PS. Neuroleptic malignant syndrome associated with atypical antipsychotic drugs. CNS Drugs. 2009;23(6): 477-492. doi:10.2165/023210-20923060-03 PubMed
4. Ananth J, Parameswaran S, Gunatilake S, et al. Neuroleptic malignant syndrome and atypical antipsychotic drugs. J Clin Psychiatry. 2004;65(4):464-470. doi:10.408/JCP.v65n0403 PubMed
5. Carroll BT, Surber SA. The problem of atypical neuroleptic malignant syndrome: a case report. Psychiatry (Edgmont). 2009;6(7):45-47. PubMed
6. Neuhut R, Lindenmayer JP, Silva R. Neuroleptic malignant syndrome in children and adolescents on atypical antipsychotic medication: a review. J Child Adolesc Psychopharmacol. 2009;19(4):415-422. doi:10.1089/cap.208.0130 PubMed
7. Picard LS, Lindsay S, Strawn JR, et al. Atypical neuroleptic malignant syndrome: diagnostic controversies and considerations. Pharmacotherapy. 2008;28(4):530-535. doi:10.1592/phco.28.4.530 PubMed (Pubitemid 351466464)
8. Yasunaga H, Yanaihara H, Fuji K, et al. Impact of hospital volume on postoperative complications and in-hospital mortality after renal surgery: data from the Japanese Diagnosis Procedure Combination Database. Urology. 2010;76(3):548-552. doi:10.1016/j.urology.2010.03.021 PubMed
9. Horiguchi H, Yasunaga H, Hashimoto H, et al. Impact of drug-eluting stents on treatment option mix for coronary artery disease in Japan. Circ J. 2010;74(8):1635-1643. doi:10.1253/circj.CJ-10-061 PubMed
10. Griswold ME, Localio AR, Mulrow C. Propensity score adjustment with multilevel data: setting your sites on decreasing selection bias. Ann Intern Med. 2010;152(6):393-395. PubMed
11. Shalev A, Hermesh H, Munitz H. Mortality from neuroleptic malignant syndrome. J Clin Psychiatry. 1989;50(1):18-25. PubMed (Pubitemid 19050611)
12. Caroff SN, Mann SC. Neuroleptic malignant syndrome. Med Clin North Am. 1993;77(1):185-202. PubMed (Pubitemid 23066804)
13. Croarkin PE, Emslie GJ, Mayes TL. Neuroleptic malignant syndrome associated with atypical antipsychotics in pediatric patients: a review of published cases. J Clin Psychiatry. 2008;69(7):1157-1165. doi:10.408/JCP. v69n0716 PubMed (Pubitemid 352031600)
14. Rosebush P, Stewart T. A prospective analysis of 24 episodes of neuroleptic malignant syndrome. Am J Psychiatry. 1989;146(6):717-725. PubMed (Pubitemid 19149581)
15. Shalev A, Munitz H. The neuroleptic malignant syndrome: agent and host interaction. Acta Psychiatr Scand. 1986;73(4):337-347. doi:10.1/j.160-047.1986. tb02694.x PubMed (Pubitemid 16071793)
16. Meyer JM. Novel antipsychotics and severe hyperlipidemia. J Clin Psychopharmacol. 2001;21(4):369-374. doi:10.1097/04714-201080-03 PubMed (Pubitemid 32673025)
17. Lindenmayer JP, Nathan AM, Smith RC. Hyperglycemia associated with the use of atypical antipsychotics. J Clin Psychiatry. 2001;62(suppl 23): 30-38. PubMed (Pubitemid 32952692)
18. Wilson DR, D'Souza L, Sarkar N, et al. New-onset diabetes and ketoacidosis with atypical antipsychotics. Schizophr Res. 2003;59(1):1-6. doi:10.1016/S0920-964(01)031-0 PubMed (Pubitemid 35284487)
19. Sobel M, Jaggers ED, Franz MA. New-onset diabetes mellitus associated with the initiation of quetiapine treatment. J Clin Psychiatry. 1999;60(8):556-557. doi:10.408/JCP.v60n0809f PubMed (Pubitemid 29413481)
20. Sumitani M, Uchida K, Yasunaga H, et al. Prevalence of malignant hyperthermia and relationship with anesthetics in Japan: data from the diagnosis procedure combination database. Anesthesiology. 2011;114(1):84-90. doi:10.1097/ALN.0b013e31820197d PubMed